All News
#0777 Big news for VEXAS! šÆ
The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV
Mrinalini Dey DrMiniDey ( View Tweet)
Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%)
Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517.
@RheumNow
Dr Shivraj Padiyar DrPadiyar ( View Tweet)
New biomarkers 14-3-3Ī· multiplex autoantibody assay improves axSpA diagnosis, especially in HLA-B27ā patients. Combined with CRP & HLA-B27, detection rose to 99% (training) & 91.4% (evaluation). In HLA-B27ā cases, 14-3-3Ī· lifted detection to 70.6% & 55%. Abstract 0531 @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0
Dr. John Cush RheumNow ( View Tweet)
#Cancers esp #hematologic & #lung are ā¬ļøin Pts w #inflammatory #rheum #diseases
Odds ratios of hem malignancies are wide
& risk stratification is imp
Are we doing a good job?
š¤skin cancer screening ??- not as per general standards
Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o
Links:
Janet Pope Janetbirdope ( View Tweet)
Do you believe that patients w #rheumatic #diseases flare if #extreme #weather?
Even 90 days after extreme weather events flares occur - loss of power, heatā med storage = ++stressful events
Is it early flare from weather & then ++stress
@RheumNow @ACRrheum #ACR25 abst#0164 https://t.co/pGPwOKrKU7
Janet Pope Janetbirdope ( View Tweet)
Why do pts with #Stillās #AOSD
Get hospitalized?
#Sepsis
1827 unweighted & 9135 Weighted #US #hospitalizations
Worse in
men
Black
Medicaid
But is it truly #infection or Stillās flare or both?
Abst#0163
ACR25 @RheumNow @rheumacr
#ACRBest as largest N ever! https://t.co/fLMNyQQNNj
Janet Pope Janetbirdope ( View Tweet)
#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In case there was any doubt:
GCA leads to ischemic vision loss
PMR does not
#ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl
David Liew drdavidliew ( View Tweet)
Leflunomide - a perennial question in GCA, that we still havenāt answered (as this meta-analysis shows), despite clear potential.
We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF?
#ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg
David Liew drdavidliew ( View Tweet)
Even when inflammation is quiet, fatigue often lingers. In 246 RA pts, 43% had significant fatigueāclosely tied to PROMs, not labs. RAPID3 < 6 flagged the few truly āfatigue-free.ā
Donāt overlook the VAS_Fatigueāit tells a real story.
@RheumNow #ACR25 Abstract# 0380
Jiha Lee JihaRheum ( View Tweet)
Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy
In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA
āļøConsider other dx if D2T PsA
#ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ
sheila RHEUMarampa ( View Tweet)
Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didnāt affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ā¬ļø CKD progression, mortality & AMI risk vs. LN pts on SGLT2is.
Interesting data but what could explain it? Further studies are needed
#ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv
sheila RHEUMarampa ( View Tweet)
#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T
Zorpocabtagene-autoleucel/MB19.1:
- 22/24 high degree efficacy
- no relapse
- no high grade CRS/ICANS
*Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Real-world JAK persistence in RA is low: <30% at 2 years across Medicare & Marketscan data (nā20K). Baricitinib lowest persistence; TOF & UPA slightly higher. Oral convenience hasnāt solved long-term adherence. Why? Safety, cost, access?
@RheumNow #ACR25 A#0369
Jiha Lee JihaRheum ( View Tweet)
Project from my group & rheum-bound resident Mary Peng!
As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) š¬
NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86ā1.41)
Reassuring for pts w/PMR!
#ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP
Mike Putman EBRheum ( View Tweet)
Only 32% of RA pts were satisfied with current txs. In a discrete choice experiment of 354 US pts, many preferred a vagus nerve stimulator over another biologic/JAKi, especially those with prior tx failures. Cost, function, and fatigue drove preferences.
@RheumNow #ACR25 A#0370
Jiha Lee JihaRheum ( View Tweet)
Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall skin (57%) PsO vs placebo at Week 16. Basket trial design enabled targeted evaluation. Safety profile favorable. Abstract 0555 @RheumNow #ACR25
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
